Phaseline

Companies › Shanghai HyaMab Biotech

Shanghai HyaMab Biotech: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PE0116–Phase 1Locally Advanced/Metastatic Solid TumorsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05801237PE0116Phase 1Locally Advanced/Metastatic Solid TumorsOncologyDec 2026
NCT05801237PE0116Phase 1Locally Advanced/Metastatic Solid TumorsOncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.